Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

Protocol for Pertussis Immunisation and Food Allergy (PIFA): a case-control study of the association between pertussis vaccination in infancy

We therefore speculate that removal of wP from the vaccine schedule contributed to the observed rise in IgE-mediated food allergy among Australian infants

Research

Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years

In women older than 25 years, the HPV 16/18 vaccine continues to protect against infections, cytological abnormalities, and lesions associated with HPV 16/18

Research

Limited impact of neonatal or early infant schedules of 7-valent pneumococcal conjugate vaccination

Early 7vPCV schedules have limited impact on pneumococcal vaccine type carriage in PNG

Research

An observational study of febrile seizures: The importance of viral infection and immunization

Determine the frequency of detection of specific viral pathogens in children with febrile seizures

Research

Influenza epidemiology in patients admitted to sentinel Australian hospitals in 2015: the Influenza Complications Alert Network

This report summarises the epidemiology of hospitalisations with laboratory-confirmed influenza during the 2015 influenza season

Research

Characterising the SARS-CoV-2 nucleocapsid (N) protein antibody response

SARS-CoV-2 nucleocapsid (N) protein antibodies can be used to identify the serological response to natural infection in those who have previously received a COVID-19 spike-based vaccine. Anti-N antibody responses can also be induced by inactivated whole SARS-CoV-2 virus vaccines, such as CoronaVac. We aimed to characterise antibody responses to the N protein following COVID-19 and following vaccination with CoronaVac.

Research

Effectiveness of nirsevimab in preventing RSV-hospitalisation among young children in Western Australia 2024

Respiratory Syncytial Virus (RSV) causes a significant burden of illness for children under 2 years of age. Nirsevimab, a long-acting monoclonal antibody, was registered for RSV prevention in Australia in 2023. In April 2024, Western Australia (WA) launched the country's first state-wide nirsevimab program for all infants and high-risk children entering their second RSV season. 

Research

The Impact of Obesity on Influenza Vaccine Immunogenicity and Antibody Transfer to the Infant During Pregnancy

Influenza vaccination is recommended for pregnant women, offering the dual benefit of protecting pregnant women and their newborn infants against influenza. This study aimed to investigate the impact of body mass index (BMI) on influenza vaccine responses in pregnant women and their newborns. 

Research

Children with otitis media mount a pneumococcal serotype specific serum IgG and IgA response comparable to healthy controls after pneumococcal conjugate vaccination

We investigated the suggestion that otitis-prone children have an impaired antibody response in the context of pneumococcal vaccination.

Research

Molecular surveillance of true nontypeable haemophilus influenzae: An evaluation of pcr screening assays

Unambiguous identification of nontypeable Haemophilus influenzae (NTHi) is not possible by conventional microbiology. Molecular characterisation of...